<DOC>
	<DOCNO>NCT02880943</DOCNO>
	<brief_summary>This prospective , multicentre , open-label , phase I/II study evaluate maximum tolerate dose ( MTD ) , successful dose ( MSD ) XOFIGO® , renal cancer patient metastases bone , without ( Group A ) ( Group B ) visceral metastasis .</brief_summary>
	<brief_title>Dose-finding , Safety Efficacy Study Radium-223 Dichloride ( XOFIGO ) RCC Patients With Bone Metastases . ( EIFFEL )</brief_title>
	<detailed_description>This prospective , multicentre , open-label , phase I/II study evaluate maximum tolerate dose ( MTD ) , successful dose ( MSD ) XOFIGO® , renal cancer patient metastases bone , without ( Group A ) ( Group B ) visceral metastasis . Dose-finding perform accord Continual Reassessment Method ( CRM ) use either toxicity ( escalation cohort ) join toxicity-efficacy ( expansion cohort ) endpoint . Two group patient evaluate : - Group A : patient bone disease mainly treat XOFIGO® alone . ( node and/or adrenal metastasis and/or ≤5 lung metastasis ≤1cm allow Group A ) . - Group B : patient already treat ongoing approve Tyrosine Kinase Inhibitor ( TKI ) visceral metastasis treat XOFIGO® bone disease . XOFIGO® administer intravenously bolus injection every 4 week maximum 6 administration per patient . Four dose level available evaluation : 27.5 kBq/kg , 55 kBq/kg , 88 kBq/kg 110 kBq/kg . Starting dose phase I 55 kBq/kg . Visit schedule : Selection Patients come hospital baseline , screen assessment must perform within 28 day prior first XOFIGO® administration . XOFIGO® period Patients receive injection XOFIGO® Day 1 4 weeks-cycle maximum 6 cycle . Patients subject physical examination , blood sample pain evaluation prior injection . Scintigraphy biodistribution radium-223 dichloride realise C1D1 1st injection XOFIGO® On C1D15 , patient also come physical examination blood sample . On C2D15 ( end DLT period phase I ) , patient also come end DLT period evaluation subject physical examination blood sampling . Prior C3D1 C5D1 , patient undergo WB-IRM FNa-PET . End treatment visit ( EOT ) take place 4 week last administration XOFIGO® . In absence confirm bone progression XOFIGO® discontinuation time , patient continue undergo WB-IRM FNa-PET every 2 month confirm bone progression end follow-up . Confirmation bone progression upon WB-IRM perform 4 week initial progression observe . Follow-up Patients followed-up maximum 12 month 1st administration XOFIGO® . Number subject : Maximum number patient enrolled escalation cohort 21 . Maximum number patient enrolled expansion cohort 21 . Group A : 2-4 patient ; Group B : 38-40 patient .</detailed_description>
	<mesh_term>Carcinoma</mesh_term>
	<mesh_term>Neoplasm Metastasis</mesh_term>
	<mesh_term>Carcinoma , Renal Cell</mesh_term>
	<mesh_term>Bone Neoplasms</mesh_term>
	<mesh_term>Bone Marrow Diseases</mesh_term>
	<mesh_term>Succinylcholine</mesh_term>
	<mesh_term>Radium Ra 223 dichloride</mesh_term>
	<criteria>1 . Histologically confirm metastatic renal cell carcinoma clear cell component . 2 . Bone metastases upon bone scan CT MRI perform time within period 4 week prior study entry , least one evaluable unidimensional bone lesion ( i.e. , ≥1 malignant tumour mass accurately measure least 1 dimension ≥ 10 mm T1weighted Magnetic Resonance Imaging [ MRI ] ) . Group A : bone metastasis ( lymph node and/or adrenal metastasis , and/or ≤ 5 lung metastasis less 1 cm , allow ) . Group B : bone metastasis AND visceral metastasis upon MRI ( accord revise RECIST 1.1 criterion ) . 3 . Patient ) first ( naïve ) , b ) second third line set receive receive approve Tyrosine Kinase Inhibitor ( patient mTOR inhibitor eligible ) . 4 . Male female , age ≥18 year ICF signature time . 5 . Eastern Cooperative Oncology Group ( ECOG ) performance status 0 1 . 6 . Good Intermediate prognostic group accord International Metastatic Database Consortium ( IMDC ) . 7 . At least 4 week end previous systemic treatment , , resolution treatmentrelated toxicity accord NCI CTCAE Version 4.03 grade ≤ 1 except alopecia . 8 . Palliative local treatment allow perform ≥ 2 week prior study entry radiotherapy , cementoplasty minor surgery ; ≥ 4 week prior study entry major surgery . 9 . Adequate organ function define follow criterion : Absolute Neutrophils count ( ANC ) ≥1 500 cells/mm3 Platelets ≥100 000 cells/mm3 Haemoglobin ≥ 9.0 g/dL AST ALT ≤ 2.5 x upper limit normal ( ULN ) , unless liver metastasis case AST ALT ≤5.0 x ULN Total bilirubin ≤ 1.5 x ULN Estimated glomerular filtration rate upon MDRD ≥ 50 mL/min Urinary protein &lt; 2+ urine dipstick . If dipstick ≥ 2+ 24hour urine collection do patient may enter urinary protein &lt; 2 g per 24 hour Corrected calcium ≤ 2.8 mmol/L . 10 . Women childbearing potential must negative serum pregnancy test within 7days prior treatment initiation . 11 . Signed date informed consent document indicate patient ( legally acceptable representative ) inform pertinent aspect trial prior enrolment . 12 . Willingness , men woman , use effective contraception study treatment 6 month last dose study drug . 13 . Willingness comply protocol requirement . Poor prognostic group accord IMDC . 2 . Prior radiotherapy ≥ 40 % bone marrow , whole pelvic irradiation and/or prior isotope therapy whatever isotope ( α βemitters ) . 3 . Active secondary cancer include prior malignancy subject diseasefree ≤ 3 year ( however , adequately treat superficial basal cell skin cervical carcinoma situ 4 week prior entry eligible study ) . 4 . Known brain leptomeningeal involvement . 5 . Any concurrent serious illness medical condition include : Crohn‟s disease ulcerative colitis Bone marrow dysplasia Known presence osteonecrosis jaw 6 . Uncontrolled hypertension . 7 . Uncontrolled cardiac arrhythmia , angina pectoris , and/or hypertension . History congestive heart failure , myocardial infarction within last 6 month . 8 . QTc interval ( QTc ) assess local device &gt; 500ms 7 day prior inclusion . 9 . Ongoing biphosphonates , denosumab and/or vitamin D supplementation . 10 . Active infection require systemic antibiotic antifungal medication . 11 . Any contraindication MRI , include : Carrying metallic medical device ( e.g . pacemaker ) foreign body prohibit use MRI Known allergy gadolinium iodine Dysthyroidism preclude usage iodine contrast agent 12 . Pregnant breast feeding . 13 . Participation another clinical trial investigational drug within 30 day prior study enrolment .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2016</verification_date>
</DOC>